Interon4.5 MIU/0.5 ml

Interon is a biologic response modifier used in a range of oncologic and viral conditions. Its use is classified below by strength of evidence.

Established / approved uses

• Hairy cell leukemia in adult patients.
• Chronic myelogenous leukemia (CML), Philadelphia chromosome-positive, chronic phase, in adult patients (often used historically before or in combination with tyrosine kinase inhibitors).
• AIDS-related Kaposi's sarcoma in adult patients with adequate CD4 counts and without systemic opportunistic infection.

Guideline-supported / historically approved uses (largely superseded)

• Chronic hepatitis B infection, as an option in select patients, generally superseded by nucleos(t)ide analogues (entecavir, tenofovir).
• Chronic hepatitis C infection, historically used alone or with ribavirin; largely replaced today by direct-acting antivirals (DAAs), and now reserved for limited settings where DAAs are unavailable or unsuitable.

Other malignancies (per specific product labeling / combination regimens)

• Certain other malignancies such as follicular non-Hodgkin's lymphoma and select renal cell carcinoma regimens, typically as adjunct or combination therapy per specialist protocols.

Use of Interon for any indication should be initiated and supervised by a physician experienced in the relevant disease area.

Each preparation of Interferon Alfa-2a [Recombinant] contains recombinant human interferon alfa-2a produced by recombinant DNA technology using genetically engineered Escherichia coli. It is available as a sterile solution (prefilled syringe/vial) or as a lyophilized powder for injection, in strengths commonly ranging from 3 million IU to 36 million IU per mL/vial, intended for subcutaneous or intramuscular injection.

Interon is a purified, sterile protein produced through recombinant DNA technology that is structurally and functionally similar to naturally occurring human interferon alfa. It exerts antiviral, antiproliferative, and immunomodulatory effects by binding to specific cell-surface interferon receptors, triggering intracellular signaling that alters gene expression relevant to cell growth control and immune response.

Interon is administered by injection under close medical supervision, primarily for selected hematologic malignancies, AIDS-related Kaposi's sarcoma, and, in some regimens, chronic viral hepatitis.

Interon belongs to the therapeutic class of biologic response modifiers, specifically classified as a recombinant interferon with combined antineoplastic, antiviral, and immunomodulatory activity.

Mechanism

Interferon Alfa-2a [Recombinant] binds to specific type I interferon receptors on the cell surface, activating the JAK-STAT intracellular signaling pathway. This induces transcription of interferon-stimulated genes, resulting in antiviral, antiproliferative, and immunomodulatory effects, including inhibition of viral replication, suppression of malignant cell proliferation, enhancement of natural killer cell and macrophage activity, and modulation of antibody production.

Pharmacokinetics

After subcutaneous or intramuscular injection, Interferon Alfa-2a [Recombinant] is well absorbed (bioavailability greater than 80%), with peak serum concentrations typically reached within 3-12 hours. It undergoes proteolytic degradation, primarily via renal metabolism, with a serum elimination half-life of approximately 3.7-8.5 hours depending on the route of administration.

Interon is given by subcutaneous or intramuscular injection, generally administered or supervised by a healthcare professional, though trained patients or caregivers may self-inject subcutaneously after proper instruction.

• Inspect the solution visually; do not use if discolored or containing particulate matter.
• Allow refrigerated product to reach room temperature before injecting; do not warm by external heat sources.
• Rotate injection sites to minimize local irritation.
• Do not shake the vial/syringe vigorously, as this may denature the protein.
• Administer at bedtime when possible to reduce the impact of flu-like symptoms.
• If a dose is missed, administer as soon as remembered unless it is close to the next scheduled dose; do not double the dose.

Clinically significant interactions with Interon include:

• Myelosuppressive agents (e.g., zidovudine, cytotoxic chemotherapy): additive bone marrow suppression; concurrent use with zidovudine in Kaposi's sarcoma treatment requires close hematologic monitoring and dose adjustment.
• Theophylline: Interon can reduce hepatic clearance of theophylline, raising serum theophylline levels and toxicity risk; monitor levels and adjust theophylline dose as needed.
• CNS depressants (opioids, sedatives, alcohol): additive central nervous system depression and neuropsychiatric effects.
• Other immunomodulatory or hepatotoxic drugs: increased risk of additive hepatotoxicity or altered immune response; use with caution and monitor liver function.

Adverse effects of Interon are dose- and duration-dependent and require ongoing monitoring.

Very common

• Flu-like syndrome: fever, chills, myalgia, headache, fatigue (especially with initial doses).
• Anorexia, nausea, and weight loss.
• Injection site reactions.
• Alopecia (usually reversible).

Serious / warranting close monitoring

• Bone marrow suppression (neutropenia, thrombocytopenia, anemia).
• Neuropsychiatric effects, including depression, irritability, and suicidal ideation/behavior.
• Autoimmune disorders, including thyroid dysfunction (hypo- or hyperthyroidism).
• Hepatotoxicity and, rarely, hepatic decompensation.
• Cardiovascular effects (arrhythmia, hypotension, rarely myocardial infarction) in susceptible patients.
• Ophthalmologic effects (retinopathy, rarely vision loss).

Interon should be used during pregnancy only if clearly needed and if the potential benefit justifies the potential risk to the fetus; women of childbearing potential should use effective contraception during treatment, and treatment should generally be avoided during pregnancy unless no safer alternative exists. Combination regimens involving ribavirin are contraindicated in pregnancy due to ribavirin's teratogenic risk.

It is not known whether Interon is excreted in human breast milk. Because of the potential for serious adverse reactions in a nursing infant, a decision should be made to discontinue breastfeeding or discontinue the drug, considering the importance of treatment to the mother; consult a physician before use while breastfeeding.

Treatment with Interon requires close medical supervision and regular laboratory monitoring (complete blood counts, liver function tests, thyroid function tests) throughout therapy.

• Neuropsychiatric effects: monitor closely for depression, suicidal ideation, aggression, or confusion; discontinue promptly if severe symptoms develop.
• Bone marrow suppression: use with caution in patients with pre-existing cytopenias; monitor blood counts regularly.
• Autoimmune disorders: Interon may induce or worsen autoimmune conditions (thyroiditis, lupus-like syndromes, psoriasis); monitor clinically and with periodic thyroid function tests.
• Cardiovascular disease: use with caution in patients with a history of cardiac disease, arrhythmia, or hypertension.
• Hepatic and renal impairment: use with caution; dose reduction or discontinuation may be needed for hepatic decompensation.
• Ophthalmologic monitoring: baseline and periodic eye exams are recommended, particularly in patients with diabetes or hypertension.
• Infections: may increase susceptibility to serious infections; monitor for signs of infection.

Specific data on Interon overdose are limited. In case of suspected overdose, seek immediate medical attention or contact emergency services/poison control. Management is supportive and symptomatic, with close monitoring of vital signs, blood counts, and organ function; there is no specific antidote. Do not attempt to manage a suspected overdose at home without medical guidance.

Store Interon in a refrigerator (2°C to 8°C); do not freeze. Protect from light. Do not shake vigorously. Keep out of reach of children, and discard any unused portion of opened multidose vials as directed on the product label.

• Elderly: use with caution; start at the lower end of the dosing range and monitor closely for toxicity, as elderly patients may be more susceptible to neuropsychiatric and cardiovascular adverse effects.
• Renal impairment: use with caution; no well-established formal dose-adjustment schedule exists, but reduced clearance may increase toxicity risk, warranting closer monitoring.
• Hepatic impairment: avoid in decompensated liver disease (see Contraindications); use cautiously with monitoring in compensated disease.
• HIV-positive patients: increased risk of myelosuppression when combined with zidovudine; monitor blood counts closely.
• Pediatric patients: see Pediatric Uses.

Duration of Interon therapy varies by indication: induction courses typically range from 10 to 24 weeks (e.g., 16-24 weeks for hairy cell leukemia, 10-12 weeks for Kaposi's sarcoma), followed by maintenance therapy for months to years depending on disease response and tolerability. For chronic viral hepatitis regimens, duration is typically 24-48 weeks, guided by virologic response. Treatment duration should be determined and periodically reassessed by the treating physician.

For presentations of Interon supplied as a lyophilized powder for injection, reconstitute using the diluent (sterile water for injection) supplied with the product. Add the diluent slowly along the vial wall, then gently swirl (do not shake) until the powder is fully dissolved. Inspect the reconstituted solution for particulate matter or discoloration before use, and use promptly per the product's specific storage instructions after reconstitution. Presentations supplied as a ready-to-use solution (prefilled syringe or solution vial) do not require reconstitution.

Interferon Alfa-2a [Recombinant] is classified under recombinant interferons / biologic response modifiers, within the broader antineoplastic and antiviral immunomodulator drug classes.

Interferon Alfa-2a [Recombinant] acts by binding to specific type I interferon receptors on target cell membranes, activating the JAK-STAT signal transduction pathway. This induces expression of interferon-stimulated genes that produce antiviral effects (inhibition of viral protein synthesis and replication), antiproliferative effects (suppression of malignant cell division), and immunomodulatory effects (enhancement of natural killer cell and cytotoxic T-cell activity, and modulation of macrophage function).

C

Safety and efficacy of Interon have not been established in pediatric patients for its oncologic and hepatitis indications, and it is generally not recommended for use in children outside of specialist protocols or clinical trials. Interon formulations preserved with benzyl alcohol are contraindicated in neonates and infants due to the risk of fatal "gasping syndrome." Any pediatric use should occur only under the direct supervision of a pediatric specialist experienced with interferon therapy.